INVO Fertility, Inc. (IVF) vs Lakewood-Amedex Biotherapeutics, Inc. (LABT)
A side-by-side comparison of INVO Fertility, Inc. and Lakewood-Amedex Biotherapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IVF
INVO Fertility, Inc.
$0.81HealthcareDelayed quote: Oct 6, 2026, 10:30 AM EDT
LABT
Lakewood-Amedex Biotherapeutics, Inc.
$0.83HealthcareDelayed quote: Oct 6, 2026, 10:29 AM EDT
Total return — IVF vs LABT
growth of $100 · dividends reinvested · last 1yIVF -61.4% (-61.4%/yr)LABT -99.0% (-99.0%/yr)IVF compounded faster over this window
Log scale — wide-divergence pair
IVF LABT
IVF vs LABT: by the numbers
- •LABT is the larger company ($1M vs $1M market cap).
- •Both run net losses; LABT's is the smaller (0.00% vs -70.18% net margin).
Metrics side by side
Valuation
| Metric | IVF | LABT |
|---|---|---|
| P/S ratio | 0.19 | N/A |
| P/B ratio | 0.09 | 0.34 |
Profitability
| Metric | IVF | LABT |
|---|---|---|
| Gross margin | 33.34% | 0.00% |
| Operating margin | -78.72% | 0.00% |
| Net margin | -70.18% | 0.00% |
| ROE | -32.05% | -169.64% |
| ROIC | -28.43% | -163.98% |
Growth (annualized)
| Metric | IVF | LABT |
|---|---|---|
| Revenue CAGR (5Y) | 39.51% | N/A |
| Total return CAGR (5Y) | -90.41% | N/A |
Go deeper
Dig into the metrics
INVO Fertility ROELakewood-Amedex Biotherapeutics ROEINVO Fertility operating marginLakewood-Amedex Biotherapeutics operating marginINVO Fertility revenue growthLakewood-Amedex Biotherapeutics revenue growthINVO Fertility free cash flowLakewood-Amedex Biotherapeutics free cash flow
INVO Fertility & Lakewood-Amedex Biotherapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.